New survey finds cancer drug shortage management remains a moving target, impacting clinical trials

The National Comprehensive Cancer Network (NCCN)—a nonprofit alliance of leading cancer centers—is publishing new results for its latest survey on cancer drug shortages in the United States. This follows data published one year ago, and six months ago, illustrating how up to 93% of centers surveyed were experiencing shortages of the crucial chemotherapy carboplatin at its peak. In June 2023, 70% of centers surveyed were also lacking adequate supply for cisplatin. In the latest survey, only 11% of surveyed centers reported a shortage of carboplatin and 7% for cisplatin; but Read More

Related posts:

  1. Further transparency needed in cancer clinical trials
  2. New study finds systematic biases at play in clinical trials
  3. Development of new techniques and clinical applications of liquid biopsy in lung cancer management
  4. Team discovers potential drug target for the lethal wasting disease known as cancer cachexia
  5. Mouse study suggests cancer drug could be used to target protein connection that spurs Parkinson’s disease
  6. Survey shows aspirin use remains high among older adults, despite risks
  7. Whose health matters? The diversity deficit in clinical trials
  8. Experts call for more clinical trials on alcohol use, liver disease

Leave a Reply

Your email address will not be published. Required fields are marked *